Bayer HealthCare progresses haemophilia trial recruitment

Bayer HealthCare has accomplished a key milestone in patient enrolment for its phase II/III trial of BAY 86-6150, a new therapy for haemophilia A and B.

Recruitment for the Trust study is now complete, bringing Bayer a step closer to gaining further understanding of the efficacy of its novel recombinant factor VIIa protein.

The drug is intended for use in patients with haemophilia A and B who have developed neutralising antibodies called inhibitors, and can help reduce dosing frequency compared to currently-available recombinant bypassing agents.

Encouraging results from an earlier phase I study have demonstrated the potential efficacy of the new therapy.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "Bayer continues to investigate innovative ways to meet the needs of people with haemophilia, including those affected by the devastating effects of inhibitors to clotting factor replacement therapies."

Earlier this week, the company received EU approval for Eylea, its new therapy for neovascular age-related macular degeneration.